- Home
- ATHA vs SWIN Comparison
ATHA vs SWIN Comparison
Compare ATHA & SWIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATHA
- SWIN
- Stock Information
- Founded
- ATHA 2011
- SWIN 2017
- Country
- ATHA United States
- SWIN Hong Kong
- Employees
- ATHA N/A
- SWIN N/A
- Industry
- ATHA Medicinal Chemicals and Botanical Products
- SWIN
- Sector
- ATHA Health Care
- SWIN
- Exchange
- ATHA Nasdaq
- SWIN Nasdaq
- Market Cap
- ATHA 21.0M
- SWIN 32.1M
- IPO Year
- ATHA 2020
- SWIN 2023
- Fundamental
- Price
- ATHA $0.26
- SWIN $1.78
- Analyst Decision
- ATHA Buy
- SWIN
- Analyst Count
- ATHA 4
- SWIN 0
- Target Price
- ATHA $11.25
- SWIN N/A
- AVG Volume (30 Days)
- ATHA 204.2K
- SWIN 73.9K
- Earning Date
- ATHA 05-14-2025
- SWIN 05-20-2025
- Dividend Yield
- ATHA N/A
- SWIN N/A
- EPS Growth
- ATHA N/A
- SWIN N/A
- EPS
- ATHA N/A
- SWIN N/A
- Revenue
- ATHA N/A
- SWIN $2,419,000.00
- Revenue This Year
- ATHA N/A
- SWIN N/A
- Revenue Next Year
- ATHA N/A
- SWIN $61.68
- P/E Ratio
- ATHA N/A
- SWIN N/A
- Revenue Growth
- ATHA N/A
- SWIN N/A
- 52 Week Low
- ATHA $0.22
- SWIN $1.16
- 52 Week High
- ATHA $3.67
- SWIN $43.60
- Technical
- Relative Strength Index (RSI)
- ATHA 42.81
- SWIN 49.56
- Support Level
- ATHA $0.23
- SWIN $1.58
- Resistance Level
- ATHA $0.27
- SWIN $1.80
- Average True Range (ATR)
- ATHA 0.03
- SWIN 0.15
- MACD
- ATHA 0.00
- SWIN -0.02
- Stochastic Oscillator
- ATHA 27.53
- SWIN 19.61
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.
About SWIN Solowin Holdings
Solowin Holdings Ltd is a investor-focused, versatile securities brokerage company in Hong Kong. It offers a wide spectrum of products and services through its secured one-stop electronic platform. It is engaged in providing securities related services, investment advisory service, and asset management service to customers. The operations were organized into four reportable segments: securities related services, investment advisory services, corporate consultancy services, and asset management services. It derives maximum revenue from investment advisory services.